Publications by authors named "Dejan Juric"

54Publications

Cell Atlas of The Human Fovea and Peripheral Retina.

Sci Rep 2020 06 17;10(1):9802. Epub 2020 Jun 17.

Department of Molecular and Cellular Biology and Center for Brain Science, Harvard University, Cambridge, MA, 02138, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-66092-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299956PMC
June 2020

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

Cell Chem Biol 2019 08 6;26(8):1067-1080.e8. Epub 2019 Jun 6.

Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2019.05.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936329PMC
August 2019

Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

N Engl J Med 2019 05;380(20):1929-1940

From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l'Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) - all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt - both in Germany (S.L.); UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Aichi Cancer Center, Nagoya (H.I.), Kanagawa Cancer Center, Yokohama (T.Y.), Saitama Cancer Center, Saitama (K.I.), and National Hospital Organization Hokkaido Cancer Center, Sapporo (M.T.) - all in Japan; Istituto Oncologico Veneto and the Departments of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy (P.C.); Vanderbilt University, Nashville (I.A.M.); Chaim Sheba Medical Center, Tel Hashomer, Israel (B.K.); National Taiwan University Hospital, Taipei (Y.-S.L.); Novartis Pharma, Basel, Switzerland (D.M., C.W.); Novartis Pharmaceuticals, East Hanover, NJ (S.H.); and Massachusetts General Hospital Cancer Center, Boston (D.J.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1813904
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1813904DOI Listing
May 2019

Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.

Breast Cancer Res Treat 2019 Jun 27;175(3):649-658. Epub 2019 Mar 27.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05206-y
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05206-yDOI Listing
June 2019

A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.

Breast Cancer Res Treat 2019 Apr 3;174(3):605-613. Epub 2019 Jan 3.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05079-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440812PMC
April 2019

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

J Clin Oncol 2018 05 5;36(13):1291-1299. Epub 2018 Feb 5.

Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research Institute and Tennessee Oncology; Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands; Mark R. Middleton, National Institute for Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Martin Schuler, West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium, Partner Site University Hospital Essen, Essen; Ruth Seggewiss-Bernhardt, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Douglas Bootle, David Demanse, Lars Blumenstein, and Cornelia Quadt, Novartis Pharma AG, Basel, Switzerland; Christina Coughlin, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.7107
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.7107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920739PMC
May 2018

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2017 Jul 14;35(19):2141-2148. Epub 2017 Mar 14.

Aditya Bardia, Steven J. Isakoff, and Dejan Juric, Massachusetts General Hospital Cancer Center; Aditya Bardia, Steven J. Isakoff, Dejan Juric, and Sara M. Tolaney, Harvard Medical School; Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, MA; Ingrid A. Mayer, Vandana Abramson, and Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jennifer R. Diamond and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Rebecca L. Moroose and Nikita C. Shah, University of Florida Health Cancer Center, Orlando, FL; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Joyce O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center; Joyce O'Shaughnessy, US Oncology, Dallas, TX; Kevin Kalinsky, Columbia University Herbert Irving Comprehensive Cancer Center; Allyson J. Ocean and Linda T. Vahdat, Weill Cornell Medicine, New York, NY; Michael Guarino, Helen F. Graham Cancer Center, Newark, DE; William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.8297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559902PMC
July 2017

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.

J Nucl Med 2016 09 14;57(9):1413-9. Epub 2016 Apr 14.

Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.115.169417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093919PMC
September 2016

Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates.

Sci Transl Med 2014 Jan;6(219):219ra9

Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3007361DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063286PMC
January 2014

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

J Clin Oncol 2012 Mar 23;30(8):765-6. Epub 2012 Jan 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.39.6390DOI Listing
March 2012

Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors.

Methods Mol Biol 2007 ;377:187-202

Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-59745-390-5_12DOI Listing
August 2007

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

J Clin Oncol 2007 Apr 20;25(11):1341-9. Epub 2007 Feb 20.

Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305-5151, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.09.3534DOI Listing
April 2007

Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.

Genes Chromosomes Cancer 2006 04;45(4):365-74

Oncology Division, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20300DOI Listing
April 2006

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.

J Clin Oncol 2006 Jan 19;24(2):274-87. Epub 2005 Dec 19.

Division of Oncology, Center for Clinical Sciences Research, Institute for Computational and Mathematical Engineering, Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305-5151, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.02.9405DOI Listing
January 2006

Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures.

Proc Natl Acad Sci U S A 2005 Dec 23;102(49):17763-8. Epub 2005 Nov 23.

Oncology Division, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305-5151, USA.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.0509082102
Publisher Site
http://dx.doi.org/10.1073/pnas.0509082102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1308932PMC
December 2005

Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.

Cancer Res 2005 Oct;65(20):9388-97

Division of Oncology, Department of Medicine and Program in Cancer Biology, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-4133DOI Listing
October 2005

Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.

Cancer Res 2005 Oct;65(19):8679-89

Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, California 94305-5151, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-05-1204DOI Listing
October 2005

High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.

Cancer Res 2005 May;65(10):4088-96

Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, California 94305-5151, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-4229DOI Listing
May 2005